Management and prophylaxis of infections after BMT/SCT

Nicholas Barber, Alison Gail Freifeld

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Fever and neutropenia HSCT preparative regimens are often marked by periods of neutropenia, during which the absolute neutrophil count (ANC) declines and remains at a low level for days or even weeks. Neutropenia as a consequence of cytoreductive chemotherapy is associated with the increased risk of serious infections (Bodey et al., 1966). This risk starts to increase when the ANC decreases to less than 1000 cells/mm3 and the infection risk increases further dramatically when ANC is less than 500 cells/mm3. Bloodstream infection develops in approximately 10%–25% of patients with an ANC less than 100 cells/mm3 (Freifeld et al., 2011; Ramphal, 2004; Wisplinghoff et al., 2003). Less often, pneumonia, cellulitis, CVC-related infections, or herpes virus reactivations will cause fever. The duration of ANC decline is also a critical determinant of infection risk, with longer durations being more likely to incur infection (Bodey et al., 1966). Full intensity HSCT recipients are typically neutropenic for at least 10–14 days or longer, and bacterial infections predominate as the infectious etiology of fever. Owing to routine prophylaxis, fungal and viral pathogens are much less common causes. Reduced-intensity HSCT regimens are generally associated with shorter and less severe neutropenic periods, but these patients remain at high risk for infection in the immediate posttransplant period due to immunosuppression. This chapter focuses on the neutropenic HSCT recipient with fever.

Original languageEnglish (US)
Title of host publicationThe BMT Data Book
Subtitle of host publicationIncluding Cellular Therapy
PublisherCambridge University Press
Pages330-347
Number of pages18
ISBN (Electronic)9781139519205
ISBN (Print)9781107617551
DOIs
StatePublished - Jan 1 2013

Fingerprint

Neutrophils
Infection
Fever
Neutropenia
Cellulitis
Bacterial Infections
Immunosuppression
Pneumonia
Viruses
Drug Therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Barber, N., & Freifeld, A. G. (2013). Management and prophylaxis of infections after BMT/SCT. In The BMT Data Book: Including Cellular Therapy (pp. 330-347). Cambridge University Press. https://doi.org/10.1017/CBO9781139519205.027

Management and prophylaxis of infections after BMT/SCT. / Barber, Nicholas; Freifeld, Alison Gail.

The BMT Data Book: Including Cellular Therapy. Cambridge University Press, 2013. p. 330-347.

Research output: Chapter in Book/Report/Conference proceedingChapter

Barber, N & Freifeld, AG 2013, Management and prophylaxis of infections after BMT/SCT. in The BMT Data Book: Including Cellular Therapy. Cambridge University Press, pp. 330-347. https://doi.org/10.1017/CBO9781139519205.027
Barber N, Freifeld AG. Management and prophylaxis of infections after BMT/SCT. In The BMT Data Book: Including Cellular Therapy. Cambridge University Press. 2013. p. 330-347 https://doi.org/10.1017/CBO9781139519205.027
Barber, Nicholas ; Freifeld, Alison Gail. / Management and prophylaxis of infections after BMT/SCT. The BMT Data Book: Including Cellular Therapy. Cambridge University Press, 2013. pp. 330-347
@inbook{089be7c807194b019214cbd9faf65422,
title = "Management and prophylaxis of infections after BMT/SCT",
abstract = "Fever and neutropenia HSCT preparative regimens are often marked by periods of neutropenia, during which the absolute neutrophil count (ANC) declines and remains at a low level for days or even weeks. Neutropenia as a consequence of cytoreductive chemotherapy is associated with the increased risk of serious infections (Bodey et al., 1966). This risk starts to increase when the ANC decreases to less than 1000 cells/mm3 and the infection risk increases further dramatically when ANC is less than 500 cells/mm3. Bloodstream infection develops in approximately 10{\%}–25{\%} of patients with an ANC less than 100 cells/mm3 (Freifeld et al., 2011; Ramphal, 2004; Wisplinghoff et al., 2003). Less often, pneumonia, cellulitis, CVC-related infections, or herpes virus reactivations will cause fever. The duration of ANC decline is also a critical determinant of infection risk, with longer durations being more likely to incur infection (Bodey et al., 1966). Full intensity HSCT recipients are typically neutropenic for at least 10–14 days or longer, and bacterial infections predominate as the infectious etiology of fever. Owing to routine prophylaxis, fungal and viral pathogens are much less common causes. Reduced-intensity HSCT regimens are generally associated with shorter and less severe neutropenic periods, but these patients remain at high risk for infection in the immediate posttransplant period due to immunosuppression. This chapter focuses on the neutropenic HSCT recipient with fever.",
author = "Nicholas Barber and Freifeld, {Alison Gail}",
year = "2013",
month = "1",
day = "1",
doi = "10.1017/CBO9781139519205.027",
language = "English (US)",
isbn = "9781107617551",
pages = "330--347",
booktitle = "The BMT Data Book",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Management and prophylaxis of infections after BMT/SCT

AU - Barber, Nicholas

AU - Freifeld, Alison Gail

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Fever and neutropenia HSCT preparative regimens are often marked by periods of neutropenia, during which the absolute neutrophil count (ANC) declines and remains at a low level for days or even weeks. Neutropenia as a consequence of cytoreductive chemotherapy is associated with the increased risk of serious infections (Bodey et al., 1966). This risk starts to increase when the ANC decreases to less than 1000 cells/mm3 and the infection risk increases further dramatically when ANC is less than 500 cells/mm3. Bloodstream infection develops in approximately 10%–25% of patients with an ANC less than 100 cells/mm3 (Freifeld et al., 2011; Ramphal, 2004; Wisplinghoff et al., 2003). Less often, pneumonia, cellulitis, CVC-related infections, or herpes virus reactivations will cause fever. The duration of ANC decline is also a critical determinant of infection risk, with longer durations being more likely to incur infection (Bodey et al., 1966). Full intensity HSCT recipients are typically neutropenic for at least 10–14 days or longer, and bacterial infections predominate as the infectious etiology of fever. Owing to routine prophylaxis, fungal and viral pathogens are much less common causes. Reduced-intensity HSCT regimens are generally associated with shorter and less severe neutropenic periods, but these patients remain at high risk for infection in the immediate posttransplant period due to immunosuppression. This chapter focuses on the neutropenic HSCT recipient with fever.

AB - Fever and neutropenia HSCT preparative regimens are often marked by periods of neutropenia, during which the absolute neutrophil count (ANC) declines and remains at a low level for days or even weeks. Neutropenia as a consequence of cytoreductive chemotherapy is associated with the increased risk of serious infections (Bodey et al., 1966). This risk starts to increase when the ANC decreases to less than 1000 cells/mm3 and the infection risk increases further dramatically when ANC is less than 500 cells/mm3. Bloodstream infection develops in approximately 10%–25% of patients with an ANC less than 100 cells/mm3 (Freifeld et al., 2011; Ramphal, 2004; Wisplinghoff et al., 2003). Less often, pneumonia, cellulitis, CVC-related infections, or herpes virus reactivations will cause fever. The duration of ANC decline is also a critical determinant of infection risk, with longer durations being more likely to incur infection (Bodey et al., 1966). Full intensity HSCT recipients are typically neutropenic for at least 10–14 days or longer, and bacterial infections predominate as the infectious etiology of fever. Owing to routine prophylaxis, fungal and viral pathogens are much less common causes. Reduced-intensity HSCT regimens are generally associated with shorter and less severe neutropenic periods, but these patients remain at high risk for infection in the immediate posttransplant period due to immunosuppression. This chapter focuses on the neutropenic HSCT recipient with fever.

UR - http://www.scopus.com/inward/record.url?scp=84923624642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923624642&partnerID=8YFLogxK

U2 - 10.1017/CBO9781139519205.027

DO - 10.1017/CBO9781139519205.027

M3 - Chapter

AN - SCOPUS:84923624642

SN - 9781107617551

SP - 330

EP - 347

BT - The BMT Data Book

PB - Cambridge University Press

ER -